ArticleEuropean journal of medical research2025
Development of a cuproptosis-related prognostic signature to reveal heterogeneity of the immune microenvironment and drug sensitivity in acute lymphoblastic leukemia.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cuproptosis: A Review on Mechanisms, Role in Solid and Hematological Tumors, and Association with Viral Infections.Mediterranean journal of hematology and infectious diseases · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundCuproptosis is a brand-new copper-dependent type of cell death that has been linked to various tumors. However, the relationship between cuproptosis and acute lymphoblastic leukemia (ALL) remains to be further elaborated.
methodsIn ALL, 12 cuproptosis-related genes (CRGs) were analyzed at genetic and single-cell levels. Two molecular clusters were identified using "ConsensusClusterPlus". With the least absolute shrinkage and selection operator, a prognostic signature was built based on cuproptosis. The prognosis, clinical parameters, biological function, immune cell infiltration, therapy sensitivities, and transcription factor regulation of the clusters and risk subsets were further compared. Kaplan Meier curves, time-ROC curves, and nomogram were employed to evaluate the accuracy of the signature. Lastly, qRT-PCR was used to detect prognostic genes in cell lines and clinical samples.
resultsCRGs exhibited extensive genetic variations and heterogeneous expression profiles in ALL. Single-cell analysis demonstrated that CRGs were strongly correlated with the biological characteristics of cancer cells. Two clusters and risk subgroups with distinct clinicopathological features, prognoses, biological functions, and drug sensitivities were identified. The cuproptosis signature was crucial in characterizing tumor immune landscape and cancer cell self-renewal ability. Furthermore, we explored that subtype A and high-scoring groups were more sensitive to immunotherapy. Multiple drugs with higher sensitivity among high-risk subgroups have been predicted. Nomograms demonstrated the clinical applicability of cuproptosis in risk assessment. The model was further validated in the verification cohort, our clinical specimens, and cell lines.
conclusionsThe cuproptosis-based model can characterize the tumor microenvironment, forecast survival results, and aid in improving risk assessment and personalized therapy options in ALL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.